{
    "clinical_study": {
        "@rank": "117717", 
        "arm_group": {
            "arm_group_label": "Arm A (ABT-199 and ketoconazole)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label multicenter, study to assess the pharmacokinetic interaction of\n      ketoconazole with ABT-199 in up to 15 subjects with relapsed or refractory non-Hodgkin's\n      lymphoma."
        }, 
        "brief_title": "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1 study designed to assess how the body processes the study drug ABT-199\n      when taken alone and in combination with ketoconazole and to assess the safety of ABT-199 in\n      combination with ketoconazole. Subjects may enroll in a separate extension study to continue\n      receiving ABT-199 after completion of this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must have relapsed or refractory non-Hodgkin's lymphoma.\n\n          -  Subject must have histologically documented diagnosis of non-Hodgkin's lymphoma as\n             defined by a B-cell neoplasm in the World Health Organization (WHO) classification\n             scheme except as noted in the exclusion criteria.\n\n          -  Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.\n\n          -  Subject must have adequate bone marrow (independent of growth factor support per\n             local laboratory reference range), coagulation, renal and hepatic function:\n\n               -  Absolute Neutrophil Count (ANC) greater than or equal to 1000/\u00b5L (without growth\n                  factor support unless neutropenia is clearly due to underlying disease);\n\n               -  Platelets greater than or equal to 75,000/mm3 (unless thrombocytopenia is\n                  clearly due to disease-related immune thrombocytopenia or to underlying disease;\n                  entry platelet count must be independent of transfusion within 14 days of\n                  Screening);\n\n               -  Hemoglobin greater than or equal to 9.0 g/dL (unless anemia is clearly due to\n                  underlying disease; entry hemoglobin must be independent of transfusion within\n                  14 days of Screening);\n\n               -  If cytopenias are present, no evidence of myelodysplastic syndrome or\n                  hypoplastic bone marrow;\n\n               -  Subject must have activated partial thromboplastin time (aPTT) and prothrombin\n                  time (PT) not to exceed 1.5 \u00d7 the upper normal limit (ULN);\n\n               -  Calculated creatinine clearance greater than or equal to 50 mL/min using a\n                  24-hour urine collection for creatinine clearance or per the Cockcroft-Gault\n                  equation;\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or\n                  equal to 3.0 \u00d7 ULN of institution's normal range;\n\n               -  Bilirubin less than or equal to 1.5 \u00d7 ULN.  Subjects with Gilbert's Syndrome may\n                  have a bilirubin greater than 1.5 \u00d7 ULN per discussion with the AbbVie medical\n                  monitor.\n\n        Exclusion Criteria:\n\n          -  Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD),\n             Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic\n             lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma\n             (MCL).\n\n          -  Subject is receiving combination anti-retroviral therapy for HIV (due to potential\n             drug-drug interactions between anti-retroviral medications and ABT-199, as well as\n             anticipated ABT-199 mechanism based lymphopenia that may potentially increase the\n             risk of opportunistic infections).\n\n          -  Subject has hypersensitivity to ketoconazole.\n\n          -  Subject has a cardiovascular disability status of New York Heart Association Class\n             greater than or equal to 2.  Class 2 is defined as cardiac disease in which patients\n             are comfortable at rest but ordinary physical activity results in fatigue,\n             palpitations, dyspnea or anginal pain.\n\n          -  Subject has a significant history of renal, neurologic, psychiatric, endocrinologic,\n             metabolic, immunologic, cardiovascular, or hepatic disease within the past 6 months\n             that in the opinion of the investigator would adversely affect his/her participating\n             in this study.\n\n          -  Subject has malabsorption syndrome or other condition which precludes enteral route\n             of administration (e.g., prior surgical resection).\n\n          -  Subject has undergone an allogeneic stem cell transplant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969669", 
            "org_study_id": "M13-364"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A (ABT-199 and ketoconazole)", 
                "description": "Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole", 
                "intervention_name": "ABT-199", 
                "intervention_type": "Drug", 
                "other_name": "GDC-0199"
            }, 
            {
                "arm_group_label": "Arm A (ABT-199 and ketoconazole)", 
                "description": "Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoconazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "non-Hodgkin's lymphoma", 
            "GDC-0199", 
            "Safety", 
            "Relapsed", 
            "Refractory", 
            "ABT-199", 
            "Pharmacokinetics", 
            "Cancer"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724-5024"
                    }, 
                    "name": "Site Reference ID/Investigator# 97498"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 97498", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756-0001"
                    }, 
                    "name": "Site Reference ID/Investigator# 92593"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 92593", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Site Reference ID/Investigator# 101415"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 101415", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199", 
        "overall_contact": {
            "email": "kaffa.fakouhi@abbvie.com", 
            "last_name": "Kaffa  Fakouhi, BS", 
            "phone": "847-935-6462"
        }, 
        "overall_contact_backup": {
            "email": "michael.dawson@abbvie.com", 
            "last_name": "Michael  Dawson, BS", 
            "phone": "847-938-9467"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Justin L Ricker, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood samples for pharmacokinetic (PK) analysis of ABT-199 will be collected at designated timepoints to assess the PK parameters for ABT-199 alone relative to ABT-199 with ketoconazole", 
            "measure": "Determination of maximum observed plasma concentration (Cmax), time to Cmax (peak time, Tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (AUC) of ABT-199", 
            "safety_issue": "No", 
            "time_frame": "Measured pre-dose and up to 96 hours post-dose ABT-199"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969669"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured up to 30 days after the last dose of study drug"
            }, 
            {
                "description": "Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study", 
                "measure": "Percentage of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured up to 30 days after the last dose of study drug"
            }, 
            {
                "description": "Body temperature, weight, blood pressure, heart rate", 
                "measure": "Change in physical exam finding, including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day 1 up to 30 days after the last dose of study drug"
            }, 
            {
                "description": "Chemistry, coagulation, hematology, urinalysis", 
                "measure": "Change in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day 1 up to 30 days after the last dose of study drug"
            }, 
            {
                "description": "Electrocardiogram", 
                "measure": "Change in cardiac assessment findings", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day 1 up to Day 12"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}